Vestnik dermatologii i venerologiiVestnik dermatologii i venerologiiВестник дерматологии и венерологии0042-46092313-6294Rossijskoe Obschestvo Dermatovenerologov i Kosmetologov63510.25208/vdv635ArticlesСтатьиResearch ArticleAntibiotic resistance of P. acnes in the treatment of acne. Ways for solving the problemАнтибиотикорезистентность P. acnes в терапии акне. Пути решения проблемыMURASHKINN NМУРАШКИНН Н

д.м.н., профессор кафедры инфекционных болезней и эпидемиологии с курсом дерматовенерологии

m_nn2001@mail.ruKrasnodar Municipal Medical Institute of Higher Education for NursesМАОУ ВПО Краснодарский муниципальный медицинский институт высшего сестринского образования15122013896NO6 (2013)№6 (2013)12813111032020Copyright ©; 2013, MURASHKIN N.N.Copyright ©; 2013, МУРАШКИН Н.Н.2013MURASHKIN N.N.МУРАШКИН Н.Н.https://creativecommons.org/licenses/by/4.0https://vestnikdv.ru/jour/article/view/635

The author describes the reasons and frequency of antibiotic resistance of P. acnes in acne patients. He reviews the strategy and methods for doctors to inhibit the prevalence of antibiotic resistance of P. acnes. The article discusses the important role of benzoyl peroxide and synergistic effect of the combination of adapalene and benzoyl peroxide in the finished form to overcome the antibiotic resistance of P. acnes and ensure the treatment efficacy.

Представлены причины и частота развития резистентности P. acnes к антибиотикотерапии у больных акне. Рассмотрены стратегия и тактика врача по ограничению распространения антибиотикорезистентности P. acnes. Обсуждается важная роль бензоила пероксида и синергетический эффект готовой комбинации адапален/бензоила пероксид в преодолении устойчивости P. acnes и достижении эффективности лечения.

P. acnesantibiotic resistanceP. acnesbenzoyl peroxideadapaleneантибиотикорезистентностьбензоила пероксидадапаленСамцов A.В. Aкне и акнеформные дерматозы. М: ЮТКОМ, 2009; 288Burkhart C., Burkhart C. Expanding the microcomedone theory and acne therapeutic: P. acnes biofilm produses biological glue that holds corneocytes together to form plug. J Am Acad Dermatol 2007; 67: 722—744.Webster G.F. Acne vulgaris. BMJ 2002; 325 (7362): 475—479.Leyden J.J., Del Rosso J.Q., Webster G.F. Clinical considerations in the treatment of acne vulgaris and other inflammatory skin disorders: focus on antibiotic resistance. Cutis 2007; 79 (6 Suppl): 9—25.Crawford W.W., Crawford I.P., Stoughton R.B. et al. Laboratory induction and clinical occurrence of combined clindamycin and erythromycin resistance in Corynebacterium acnes. J Invest Dermatol 1979; 72 (4): 187—190.Cunliffe W.J., Holland K.T., Bojar R. et al. A randomized, double-blind comparison of a clindamycin phosphate/benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris. Clin Ther 2002; 24 (7): 1117—1133.Leyden J., Kaidbey K., Levy S.F. The combination formulation of clindamycin 1% plus benzoyl peroxide 5% versus 3 different formulations of topical clindamycin alone in the reduction of Propionibacterium acnes. An in vivo comparative study. Am J Clin Dermatol 2001; 2: 263—266.Schafer F., Fich F., Lam M. et al. Antimicrobial susceptibility and genetic characteristics of Propionibacterium acnes isolated from patients with acne. Int J Dermatol 2013; 52 (4): 418—425.Harkaway K.S., McGinley K.J., Foglia A.N. et al. Antibiotic resistance patterns in coagulase-negative staphylococci after treatment with topical erythromycin, benzoyl peroxide, and combination therapy. Br J Dermatol 1992; 126 (6): 586—590.Vowels B.R., Feingold D.S., Sloughfy C. et al. Effects of topical erythromycin on ecology of aerobic cutaneous bacterial flora. Antimicrob Agents Chemother 1996; 40 (11): 2598—2604.Nast A., Dreno B., Bettoli V. et al. European Evidence-based (S3) Guidelines for the Treatment of Acne. J Eur Acad Dermatol Venereol 2012; 26 (Suppl. 1): 1—29.Mills O. Jr., Thornsberry C., Cardin C.W. et al. Bacterial resistance and therapeutic outcome following three months of topical acne therapy with 2% erythromycin gel versus its vehicle. Acta Derm Venereol 2002; 82 (4): 260—265.Аравийская Е.Р., Красносельских Т.В., Соколовский Е.В. Aкне. В: Кожный зуд. Aкне. Урогенитальная хламидийная инфекция / Под ред. Е.В. Соколовского. СПб: Сотис, 1998; 68—100Rosen T. Antibiotic resistance: an editorial review with recommendations. J Drugs Dermatol 2011; 10 (7): 724—733.Burke B., Eady E.A., Cunliffe W.J. Benzoyl peroxide versus topical erythromycin in the treatment of acne vulgaris. Br J Dermatol 1983; 108: 199—204.Swinyer L.J., Baker M.D., Swinyer T.A., Mills O.H. A comparative study of benzoyl peroxide and clindamycin phosphate for treating acne vulgaris. Br J Dermatol 1988; 199: 615—622.Gollnick H., Cunliffe W., Berson D. et al. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol 2003; 49 (1 Suppl): S1—37.Thiboutot D.M., Shalita A.R., Yamauchi P.S. et al. Adapalene gel, 0.1%, as maintenance therapy for acne vulgaris: a randomized, controlled, investigator-blind follow-up of a recent combination study. Arch Dermatol 2006; 142 (5): 597—602.Leyden J., Thiboutot D.M., Shalita A.R. et al. Comparison of tazarotene and minocycline maintenance therapies in acne vulgaris: a multicenter, doubleblind, randomized, parallel-group study. Arch Dermatol 2006; 142 (5): 605—612.Feldman S.R., Tan L., Poulin Y. et al. The efficacy of adapalene-benzoyl peroxide combination increases with number of acne lesions. J Am Acad Dermatol 2011; 64 (6): 1085—1091.Leyden J.J., Preston N., Osborn C., Gottschalk R.W. In-vivo effectiveness of adapalene 0.1%/benzoyl peroxide 2.5% gel on antibiotic-sensitive and resistant Propionibacterium acnes. J Clin Aesthet Dermatol 2011; 4: 22—26.Gold L.S., Tan J., Cruz-Santana A. et al. A North American study of adapalene-benzoyl peroxide combination gel in the treatment of acne. Cutis 2009; 84: 110—116.